Hematopoiesis is a complex process, which takes place in the bone marrow microenvironment in a so-called hematopoietic niche.
(sKitL) form bone marrow stromal cells, which promotes the transfer of EC and HSC from quiescence state to proliferation [47] . A smooth transition of hematopoietic stem cells through the blood vessel wall is necessary for their effective mobilization from the bone marrow niche and engraftment after transplantation. MMP-9 allows this transmigration through the partial degradation of the sub-endothelial basement membrane, composed primarily of type IV collagen, which results in effective diapedesis [43] . IL-10 activates tissue inhibitor of metalloproteinases 1 (TIMP-1), which downregulates expression of MMP-9 and promotes HSC adhesion to the bone marrow osteoblastic niche and hematological reconstitution [48] . In HSC mobilization, G-CSF stimulates the release of proteolytic enzymes from neutrophils, including metalloproteinases and leads to profound changes in the HSC microenvironment [49] . G-CSF exerts its activity not only by binding with its receptor on neutrophils and HSCs but also via an indirect mechanism since the presence of a G-CSF receptor is not solely required for mobilization [49] . During G-CSF-mediated mobilization neutrophil degranulation occurs leading to upregulation of the matrix metalloproteases [50] . 
SDF-1
Stromal cell-derived factor 1 (SDF-1, CXCL12) is a key protein in the migration and proliferation of cells that have a CXCR4 receptor on their surface, e.g. HSC, EC, and cancer cells [52] . Upregulated expression of CXCR4 is a predictor of poor prognosis in many malignancies. In the course of AML and B-cell ALL, overexpression of CXCR4 on CD34 positive cells is observed [53, 54] The expression of cytokines active in angiogenesis as well as those responsible for maintenance of the homeostasis in hematopoietic niche is modulated by miRNAs.
MicroRNAs
MicroRNAs (miRNAs) are class of small ~ 22 nucleotides (19-25), endogenous non-coding RNAs, which play an important role in post-transcriptional regulation of gene expression [59] [60] [61] . By targeting the 3' untranslated regions (UTRs) of messenger RNA (mRNA), miRNAs repress translation, which leads to mRNA degradation and therefore downregulation of gene expression [62] [63] [64] .
These molecules participate in the regulation of vital processes such as cell proliferation, differentiation, and apoptosis [65] [66] [67] [68] [69] . Targeting the bone marrow niche gene pathways and cytokines certain miRNAs can modulate angiogenesis, mobilization of HSC and homing after transplantation [70] [71] [72] . The role of selected miRNAs in hematopoiesis is presented in table I.
miRNA-15a/-16
Variable expression of miRNA-15a/-16 influence the pathogenesis of most human cancers, like prostate, colon cancer, and hematological malignancies: multiple myeloma, B-cell lymphoma, leukemia and polycythemia vera [72] [73] [74] 76] . Development and progression of malignancies are closely associated with angiogenesis. It has been shown that VEGF activity is negatively regulated by expression of miRNA-15a/-16. In myeloma cells, miRNA-15a/-16 expression inversely correlates with VEGF. Downregulation of the miRNA-15a/-16 cluster increases the proangiogenic activity of myeloma cells [77] .
MiRNA-16 is involved in normal erythropoiesis, while deregulation of this miRNA contributes to abnormal erythroid lineage in polycythemia vera [72] . Apart from the influence on the development of cancer, miRNA-15a/-16 is associated with chemoresistance. It has been shown that low level of these miRNAs reduces apoptosis, increases proliferation of tumor cells and angiogenesis [78] . Downregulation of the miRNA-15a/-16 level inversely correlates with the expression of oncogenes BCL-2 and BCL-XL in myeloma cells and neoplastic B cells [76, 79] . Deregulation of miRNA-15a/-16 expression may affect the efficacy of chemotherapy. The resistance to apoptosis, induced by a low level of miRNA-15a/-16 reduces the activity of cytarabine [80] . 
miRNA-126
Cytokines and adhesion molecules regulate the migration of HSC between the hematopoietic niche and the peripheral blood.
MiRNA-126 is involved in this process by targeting VCAM-1 [81] . MiRNA-15a/-16 cluster plays also a significant role in ZFP91/NK-κB/ HIF-1α pathway [85] . MiRNA-126 regulates angiogenesis and tumor development by controlling the expression of targeted VEGF signaling repressors (sprouty-related, EVH1 domain-containing protein -Spred-1 and phosphoinositide-3-kinase regulatory subunit 2 -PIK3R2) [86] . High expression of this miRNA in endothelial cells downregulates Spred-1 and PIK3R2 and promotes angiogenesis, while low expression of miRNA-126 leads to elevation of VEGF repressors, inhibition of ANGPT1 and impairment of blood vessels formation [86] [87] [88] [89] .
miRNA-146a
MiRNA-146a is an important molecule influencing inflammation and tumorigenesis. Expression of this miRNA is induced by the NF-κB protein complex, which plays a significant role in inflammatory response [90] . MiRNA-146a regulates mobilization of HSC as well as their homing after bone marrow transplantation [90] [91] [92] [93] . Previous research has shown that under the influence of G-CSF, expression of CXCR4 chemokine receptor mRNA and protein in AML cells was decreased while the level of miRNA-146a was increased [94] . MiRNA-146a affects the CXCR4 mRNA, which leads to disruption of the SDF-1/ CXCR4 signaling pathway. It results in more efficient mobilization of HSCs, and slower homing [94] . Urocinase-type plasminogen activator receptor (uPAR), known to be modulated by miRNA-146a, by binding vitronectin is involved in extracellular matrix degradation, cell adhesion, and migration. It also allows cross-talk with CXCR4.
Under GCS-F stimulation, uPAR enhances chemotactic response to SDF-1. MiRNA-146a downregulates uPAR/CXCR4 pathway, which leads to migration engraftment, and adhesion of hematopoietic stem progenitor cells (HSCPC) to the bone marrow niche [95, 96] .
Through downregulating of superoxide dismutase 2 enzyme (SOD2)
expression, miRNA-146a increases apoptosis and sensitivity to chemotherapy of cancer cells, by enhancement of reactive oxygen species (ROS) generation [97] .
miRNA-223
MiRNA-223 is a diagnostic biomarker in the course of obesity, atherogenesis, numerous solid tumors, such as lung, colon, prostate and hematological malignancies [98] [99] [100] [101] [102] . Moreover, miRNA-223 expression is associated with hematopoiesis, differentiation and maturation of hematopoietic progenitor cells (HPC) [103] .
MiRNA-223 stimulates granulopoiesis, erythroid, and megakaryocyte differentiation via targeting NFI-A, IGF-1R, and LMO2 genes. It is also crucial for homeostasis of mature neutrophils, and limits inflammation [103, 104] . Using transcription factors (TF) miRNA-223 is associated with regulation of network-specific signaling for HPC and differentiation of hematopoietic lines. MiRNA-223 is responsible for the appropriate development, and maturation of myeloid progenitors to granulocytic, erythroid, as well as monocyte/macrophage lines [103, 105] .
During macrophage differentiation, miRNA-223 cooperates with miRNA-15a/-16 cluster targeting IKK inhibitor gene, which results in stimulation of NF-κB signaling pathway [104, 106] . Low miRNA-223 expression influence limited expansion of HSC progenitors.
High-level expression of granulocyte-macrophage progenitors (GMP)
is linked to a deficiency of miRNA-223 in mice [107] . In contrast, the progress of human granulopoiesis and progenitor cells differentiation is associated with higher expression of this molecule [104, 107] . Downregulation of miRNA-223 is an important factor for monocyte differentiation [108] . In hematological malignancies, miRNA-223 in bone marrow seems to be tumor-suppressive molecule [104] .
MiRNA-223 is involved in neoplastic cells development. This miRNA modulates apoptosis by targeting oncogene BCL-2 and insulin growth factor 1 receptor (IGF-1R) [109] . Upregulated expression of miRNA-223 is observed in favorable adult AML risk groups, while in B-cell malignancies (diffuse large B-cell lymphoma, Burkitt lymphoma, chronic lymphocytic leukemia) expression alterations of this miRNA may influence development of lymphoid lineage [102, 105] .
We evaluated the kinetics of circulating miRNA-15a, miRNA-16, miRNA-126 and miRNA-146a as well as miRNA-223 in the group of patients with lymphoproliferative malignancies before autologous HSCT and early after transplantation [93] . We observed a correlation of miRNA-15a, miRNA-16, miRNA-126 and miRNA-146 levels assessed directly after conditioning treatment with time to engraftment. Moreover, the level of miRNA-15a/16, evaluated just after chemotherapy, positively correlated with the ANGPT1/ ANGPT2 ratio. Additionally, low levels of miRNA-15a, miRNA-146a, and miRNA-223 at the nadir of aplasia were associated with faster engraftment [93] . The other interesting observation in our study was the correlation of miRNA-146a with MMP-9 level directly after chemotherapy and at the nadir of aplasia [93] . Due to a complicated 
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